ResearchThe genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in neuroendocrine neoplasms (NENs) including small-cell lung cancer (SCLC)
ResearchMultiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities
ResearchExercise Counseling and Referral Practices Among Oncology Care Physicians in Latin America: A Multinational Survey Study
ResearchAnti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis
ResearchCreatine Supplementation in Preclinical Models Receiving Immune Checkpoint Inhibitor Therapy: A Systematic Review
ResearchGeographic, Temporal, and Sex-Specific Trends in Mesothelioma Burden in the United States, 1990-2023
ResearchTarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases
ResearchMultiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum
ResearchBeyond Testing: Rethinking Access in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
ResearchLiquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction
ResearchRecent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US
ResearchCost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer
ResearchNeladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study